Your session is about to expire
← Back to Search
Device
iRF System Hepatic Denervation for Type 2 Diabetes (DeLIVER Trial)
N/A
Waitlist Available
Research Sponsored by Metavention
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30, 90, 180 and 365 days
Awards & highlights
DeLIVER Trial Summary
This trial is testing a new device to see if it safely improves glycemic control in type 2 diabetes patients.
DeLIVER Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30, 90, 180 and 365 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30, 90, 180 and 365 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Rate of Serious Adverse Device Effects
Secondary outcome measures
Adverse Event rate 365 days
Change in glycemic control - C-peptide
Change in glycemic control - FPG
+4 moreDeLIVER Trial Design
1Treatment groups
Experimental Treatment
Group I: Hepatic DenervationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
iRF System Hepatic Denervation
2020
N/A
~20
Find a Location
Who is running the clinical trial?
MetaventionLead Sponsor
3 Previous Clinical Trials
121 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
California
How old are they?
65+
What site did they apply to?
Stanford University Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Share this study with friends
Copy Link
Messenger